drugset
Drugs / LUTETIUM LU 177 ZADAVOTIDE GURAXETAN
last change Aug 2026 re-read 9 days ago

LUTETIUM LU 177 ZADAVOTIDE GURAXETAN

also known as [177Lu]Lu-PSMA I&T · 177Lu-PNT2002 · Pnt2002 lu-177 · Zadavotide guraxetan lutetium lu-177

Other / unclassified

Developed for
prostate cancer · adenoid cystic carcinoma · cancer · clear cell renal carcinoma
Investigated by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Medical University of Vienna · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Adenoid Cystic Carcinoma Research Foundation · Glenn Bauman · Lantheus Medical Imaging
+3 more · London Health Sciences Foundation · Merck Sharp & Dohme LLC · Progenics Pharmaceuticals, Inc.

Trials 7

today NCT06361810 · Ph 1/2 NCT06322576 · Ph 2 NCT06259123 · Ph 2 NCT06220188 · Ph 2 NCT05893381 · Ph 2 NCT05867615 · Ph 2 NCT05230251 · Ph 1/2
2022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT06361810 Oct 2025 → Jan 2031 clear cell renal carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Withdrawn No outcome recorded Stop: Business
Phase 1/2 NCT05230251 Mar 2022 → Sep 2023 prostate cancer Glenn Bauman Completed No outcome recorded
Phase 25 trials
Phase 2 NCT06322576 Feb → Nov 2025 adenoid cystic carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Terminated No outcome recorded
Phase 2 NCT06259123 Feb 2024 → Jan 2027 expected prostate cancer Medical University of Vienna Recruiting No outcome recorded
Phase 2 NCT06220188 Jan 2024 → Jun 2026 overdue prostate cancer Medical University of Vienna Recruiting No outcome recorded
Phase 2 NCT05893381 Jun 2023 → Sep 2027 expected prostate cancer Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Recruiting No outcome recorded
Phase 2 NCT05867615 May 2023 → Aug 2026 overdue cancer Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Active not recruiting No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as LUTETIUM LU 177 ZADAVOTIDE GURAXETAN ChEMBL registry synonym — accepted as the source's own label CHEMBL5314936 ↗
Known as 177Lu-PNT2002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361810 ↗
2

NCT05230251 ↗

NCT06322576 ↗
Known as [177Lu]Lu-PSMA I&T ClinicalTrials.gov intervention name — accepted as the source's own label NCT06220188 ↗
3

NCT05867615 ↗

NCT06259123 ↗

NCT05893381 ↗
Known as Pnt2002 lu-177 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314936 ↗
Known as Zadavotide guraxetan lutetium lu-177 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314936 ↗
Modality Other / unclassified “Lutetium-177 PSMA Radioligand Therapy (RLT)” PMID 37081426 ↗ Apr 2023
Route Intravenous “administered intravenously” NCT05230251 ↗